Moxifloxacin (Avelox)
moxifloxacin hydrochloride
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Community-acquired pneumonia (including MDRSP) | Adults ≥18 years | Monotherapy | FDA Approved |
| Uncomplicated skin & skin structure infections | Adults ≥18 years | Monotherapy | FDA Approved |
| Complicated skin & skin structure infections | Adults ≥18 years | Monotherapy | FDA Approved |
| Complicated intra-abdominal infections | Adults ≥18 years | Monotherapy | FDA Approved |
| Plague (pneumonic & septicemic; prophylaxis) | Adults ≥18 years | Monotherapy | FDA Approved |
| Acute bacterial sinusitis | Adults ≥18 years | Monotherapy (reserve — no alternative) | FDA Approved |
| Acute bacterial exacerbation of chronic bronchitis | Adults ≥18 years | Monotherapy (reserve — no alternative) | FDA Approved |
Moxifloxacin carries a broad spectrum encompassing gram-positive organisms (including multi-drug resistant S. pneumoniae), gram-negative bacteria, atypical pathogens (Mycoplasma, Chlamydophila), and anaerobes (Bacteroides fragilis). The FDA label explicitly reserves moxifloxacin for acute bacterial sinusitis and ABECB only when no alternative treatment options exist, owing to the risk of serious fluoroquinolone-class adverse reactions (FDA PI). For community-acquired pneumonia, moxifloxacin remains a first-line option in current IDSA/ATS guidelines for patients with comorbidities or risk factors for drug-resistant organisms.
Multidrug-resistant tuberculosis (MDR-TB): Moxifloxacin is recommended as a core agent in MDR-TB regimens by ATS/IDSA/CDC/ERS guidelines. Dose 400 mg daily within a multi-drug regimen; higher doses (600–800 mg) have been explored in WHO-endorsed short-course regimens. Evidence quality: High.
Drug-susceptible TB — 4-month shortened regimen: CDC Study 31/A5349 demonstrated noninferiority of a 4-month rifapentine-moxifloxacin regimen vs standard 6-month therapy (CDC MMWR 2022). Evidence quality: High (phase III RCT).
Tuberculous meningitis: Used as a component of intensified regimens given excellent CNS penetration. Evidence quality: Moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CAP — outpatient, comorbidities present | 400 mg PO daily | 400 mg PO daily | 400 mg/day | 7–14 days; covers MDRSP and atypicals IV-to-PO switch is 1:1; no dose change needed |
| CAP — inpatient, step-down therapy | 400 mg IV daily | 400 mg PO daily | 400 mg/day | 7–14 days total; infuse IV over 60 min Switch to oral when clinically stable |
| Uncomplicated SSSI (abscess, cellulitis, impetigo) | 400 mg PO daily | 400 mg PO daily | 400 mg/day | 7 days; MSSA and S. pyogenes coverage |
| Complicated SSSI (deep abscess, infected ulcer) | 400 mg IV daily | 400 mg PO daily | 400 mg/day | 7–21 days; surgical source control essential Sequential IV→PO at physician discretion |
| Complicated intra-abdominal infection | 400 mg IV daily | 400 mg PO daily | 400 mg/day | 5–14 days; covers anaerobes including B. fragilis No additional anaerobic cover needed |
| Plague — treatment and prophylaxis | 400 mg PO/IV daily | 400 mg PO/IV daily | 400 mg/day | 10–14 days; start ASAP after exposure Approved based on animal efficacy study |
| Acute bacterial sinusitis (reserve use) | 400 mg PO daily | 400 mg PO daily | 400 mg/day | 10 days; only when no alternative exists FDA reserves due to fluoroquinolone class risks |
| ABECB (reserve use) | 400 mg PO daily | 400 mg PO daily | 400 mg/day | 5 days; only when no alternative exists |
Moxifloxacin uses a single 400 mg dose across all approved indications with no renal or hepatic dose adjustment required. The only variable is duration, which ranges from 5 days (ABECB) to 21 days (complicated SSSI). The IV formulation is bioequivalent to oral and can be switched 1:1 when the patient tolerates oral intake. Administer tablets at least 4 hours before or 8 hours after antacids, iron, or multivitamins containing divalent/trivalent cations (FDA PI).
Pharmacology
Mechanism of Action
Moxifloxacin exerts bactericidal activity by simultaneously inhibiting two essential bacterial enzymes: DNA gyrase (topoisomerase II) and topoisomerase IV. These enzymes are critical for DNA replication, transcription, repair, and recombination. By trapping the enzyme-DNA complex and preventing strand re-ligation, moxifloxacin introduces lethal double-strand breaks in bacterial DNA. The 8-methoxy group on the quinolone ring enhances activity against gram-positive organisms and anaerobes compared with earlier fluoroquinolones, while also reducing the potential for phototoxicity. The dual-target mechanism raises the barrier to resistance development, as organisms typically require mutations in both targets simultaneously. Cross-resistance with other fluoroquinolones can occur through mutations in gyrA or gyrB genes, efflux pump upregulation, or decreased outer membrane permeability.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~90% oral bioavailability; Tmax ~1–3 h; Cmax 3.1 mg/L (single dose) | High oral bioavailability allows reliable PO dosing; food does not affect absorption; yogurt does not alter AUC |
| Distribution | Vd 1.7–2.7 L/kg; 30–50% protein bound; tissue:plasma ratios up to 21:1 in alveolar macrophages | Excellent tissue penetration into respiratory tract, sinuses, skin, and abdominal tissues; concentrations in alveolar macrophages far exceed plasma |
| Metabolism | Phase II conjugation: sulfate (M1, ~38%) and glucuronide (M2, ~14%); CYP system not involved | No CYP-mediated drug interactions; does not inhibit CYP3A4, 2D6, 2C9, 2C19, or 1A2; metabolites are microbiologically inactive |
| Elimination | t½ 12 ± 1.3 h; ~20% unchanged in urine, ~25% unchanged in feces; total body clearance 12 L/hr | Once-daily dosing; no dose adjustment for renal impairment (including HD/CAPD) or hepatic impairment (Child-Pugh A–C) |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 7% | Most frequent GI complaint; usually self-limiting; take with or without food |
| Diarrhea | 6% | Distinguish from C. difficile-associated diarrhea, particularly if persistent or bloody |
| Headache | 4% | Dose-independent; typically resolves without intervention |
| Dizziness | 3% | Advise caution with driving or operating machinery until response is known |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Vomiting | 2% | May require antiemetic; assess for dehydration |
| Constipation | 2% | Usually mild; encourage adequate hydration |
| Abdominal pain | 2% | Non-specific; rule out surgical abdomen in cIAI patients |
| Insomnia | 2% | CNS class effect; consider morning dosing |
| Pyrexia | 1% | Distinguish drug fever from underlying infection |
| ALT elevation | 1% | Usually transient; monitor if baseline LFTs are abnormal |
| Dyspepsia | 1% | Consider timing relative to meals |
| Hypokalemia | 1% | Important: hypokalemia increases QT prolongation risk; correct before starting therapy |
| Anemia | 1% | Check baseline CBC in patients with risk factors |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Tendinitis / tendon rupture | Rare (~0.1–0.4%) | Hours to months post-treatment | Discontinue immediately; rest affected limb; avoid all fluoroquinolones permanently |
| QT prolongation / torsade de pointes | 0.1–1% (QTc prolongation noted in trials) | Within first days of therapy | Obtain baseline ECG in at-risk patients; discontinue if QTc >500 ms or increases >60 ms; correct electrolytes |
| Peripheral neuropathy | Rare | Days to weeks; may be irreversible | Discontinue at first sign of pain, burning, tingling, or numbness; may be permanent |
| CNS effects (psychosis, seizures, hallucinations) | Rare (<0.1%) | Often within first 1–2 doses | Discontinue immediately; institute supportive care; avoid all fluoroquinolones |
| Clostridioides difficile-associated diarrhea | Uncommon (~0.5–2%) | During or up to 2 months after therapy | Test for C. difficile toxin; discontinue moxifloxacin; treat with vancomycin or fidaxomicin |
| Hepatitis / acute hepatic failure | Very rare (postmarketing reports, including fatalities) | Days to weeks | Discontinue at first sign of jaundice or hepatic dysfunction; supportive care |
| Anaphylaxis / severe hypersensitivity | Very rare | Minutes to hours; may follow first dose | Emergency treatment; epinephrine; permanent discontinuation of all quinolones |
| Stevens-Johnson syndrome / TEN | Very rare | 1–3 weeks | Discontinue immediately; dermatology referral; supportive care |
| Aortic aneurysm / dissection | Rare (epidemiologic association) | Within 2 months of use | Reserve use in patients with known aortic aneurysm or high-risk features; urgent vascular evaluation if symptoms develop |
| Myasthenia gravis exacerbation | Rare (postmarketing, including deaths) | Variable | Contraindicated in known myasthenia gravis; discontinue if worsening weakness occurs |
| Blood glucose disturbances (hypo- and hyperglycemia) | Uncommon; severe cases rare | Variable; predominantly in diabetic patients on concurrent hypoglycemics | Close glucose monitoring in diabetics; discontinue if severe hypoglycemia occurs |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Nausea | >0.3% | Most common cause with oral dosing |
| Diarrhea | >0.3% | Leading cause with sequential IV/PO |
| Dizziness | >0.3% | Oral therapy |
| Vomiting | >0.3% | Oral therapy |
| Rash | >0.3% | Leading cause with IV-only therapy; evaluate for hypersensitivity |
The mean QTc increase with oral moxifloxacin is approximately 6 ms (± 26); with IV dosing, approximately 10 ms on day 1. While no excess cardiovascular mortality was observed in over 15,500 controlled-trial patients or in a postmarketing observational study of over 18,000 patients, clinicians should correct hypokalemia and hypomagnesemia before initiating therapy, avoid concurrent Class IA/III antiarrhythmics, and consider baseline ECG in patients with cardiac risk factors (FDA PI).
Drug Interactions
Moxifloxacin is metabolized exclusively via phase II conjugation (glucuronidation and sulfation) without any involvement of the cytochrome P450 system. It does not inhibit CYP3A4, 2D6, 2C9, 2C19, or 1A2 in vitro, which substantially limits pharmacokinetic drug-drug interactions. The primary interaction concerns are chelation with polyvalent cations (reducing absorption) and pharmacodynamic additive QT prolongation.
In formal PK interaction studies, moxifloxacin showed no clinically meaningful interaction with atenolol, theophylline, itraconazole, morphine, probenecid, ranitidine, cyclosporine, glyburide, or oral contraceptives (FDA PI). This favourable profile is directly attributable to moxifloxacin’s non-CYP metabolism.
Monitoring
-
ECG (QTc)
Baseline
Trigger-based Obtain baseline ECG in patients with cardiac risk factors, hepatic cirrhosis, known QT prolongation, or receiving concurrent QT-prolonging drugs. Repeat if symptoms of arrhythmia develop. Discontinue if QTc exceeds 500 ms or increases by more than 60 ms from baseline. -
Electrolytes (K⁺, Mg²⁺)
Baseline
Routine Correct hypokalemia and hypomagnesemia before initiating moxifloxacin. Recheck if diarrhea, vomiting, or concurrent diuretic use occurs during therapy. -
Hepatic Function
Baseline; if symptoms arise
Trigger-based Assess LFTs at baseline in patients with pre-existing liver disease. Discontinue immediately if jaundice, dark urine, or markedly elevated transaminases develop during therapy. -
Tendon Assessment
Throughout therapy
Routine Ask about tendon pain, swelling, or inflammation at each visit. Risk is higher in patients >60 years, those on corticosteroids, and organ transplant recipients. Discontinue at the first sign of tendinitis. -
Neurological Status
Throughout therapy
Routine Monitor for signs of peripheral neuropathy (tingling, numbness, weakness) and CNS effects (confusion, hallucinations, seizures). Discontinue immediately if these develop. -
Blood Glucose
Throughout therapy
Trigger-based Closely monitor glucose in diabetic patients, particularly those on sulfonylureas or insulin. Severe hypoglycemia (including coma) has been reported. -
Stool Assessment
If diarrhea develops
Trigger-based Test for C. difficile toxin if diarrhea is persistent, watery, or bloody, or if it develops during or up to 2 months after completing moxifloxacin therapy.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to moxifloxacin or any member of the quinolone class
- Myasthenia gravis — fluoroquinolones may exacerbate muscle weakness; postmarketing deaths and ventilatory failure reported
Relative Contraindications (Specialist Input Recommended)
- Known QT prolongation or congenital long QT syndrome — documented baseline QTc prolongation warrants use of an alternative agent
- Concurrent Class IA or III antiarrhythmic therapy — additive risk of torsade de pointes
- Known aortic aneurysm or high-risk features (Marfan syndrome, elderly with hypertension, peripheral vascular disease) — epidemiologic data suggest increased risk of aortic dissection within 2 months of fluoroquinolone use
- History of fluoroquinolone-associated tendon disorder — prior tendinitis or rupture with any fluoroquinolone contraindicates rechallenge
- Pregnancy — animal studies demonstrate fetal skeletal variations and reduced neonatal survival at maternally toxic doses; no human data
Use with Caution
- Elderly patients (≥60 years) — increased risk of tendon rupture and QT prolongation
- Concurrent corticosteroid therapy — independently increases tendon rupture risk
- Organ transplant recipients — elevated tendon disorder risk
- Hepatic cirrhosis (any Child-Pugh class) — metabolic disturbances may amplify QT prolongation; ECG monitoring advised
- Uncorrected electrolyte abnormalities (hypokalemia, hypomagnesemia) — correct before initiating therapy
- Known seizure disorder or CNS pathology — may lower seizure threshold
- Diabetic patients on insulin or sulfonylureas — risk of severe hypoglycemia
- Patients under 18 years — not approved; arthropathy observed in immature animals; limited safety data (pediatric cIAI trial showed 4.3% musculoskeletal adverse events)
Fluoroquinolones, including moxifloxacin, carry a class-wide boxed warning for disabling and potentially irreversible adverse reactions affecting tendons, the peripheral nervous system, and the central nervous system. These reactions may occur together in the same patient and can appear within hours to weeks of starting treatment. Additionally, fluoroquinolones may exacerbate muscle weakness in patients with myasthenia gravis. The label mandates immediate discontinuation at the first signs of any of these reactions and states that moxifloxacin should be reserved for acute bacterial sinusitis and ABECB only when no alternative treatment is available (FDA PI, revised July 2025).
Patient Counselling
Purpose of Therapy
Moxifloxacin is a prescription antibiotic used to treat certain bacterial infections, including pneumonia, skin infections, abdominal infections, and sinus infections. It works by killing bacteria that cause these infections. It should only be used for bacterial infections and will not work against viruses such as the common cold or influenza.
How to Take
Take one 400 mg tablet once daily, with or without food, along with plenty of fluids. If a dose is missed, take it as soon as remembered unless fewer than 8 hours remain before the next scheduled dose — in that case, skip the missed dose and continue with the usual schedule. Never take a double dose. Complete the full course of treatment even if symptoms improve, as stopping early may allow bacteria to become resistant.
Sources
- Avelox (moxifloxacin) tablets and injection prescribing information. Bayer HealthCare Pharmaceuticals. Revised July 2025. FDA Label Primary source for all approved indications, dosing, adverse reactions, pharmacokinetics, and contraindications cited in this monograph.
- FDA Safety Communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics. July 2018. FDA.gov Regulatory basis for glucose monitoring recommendations and mental health adverse effect warnings.
- FDA Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics. December 2018. FDA.gov Source for the aortic aneurysm and dissection warning in the contraindications section.
- Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577-1587. doi:10.1056/NEJMoa1407426 REMoxTB phase III trial evaluating moxifloxacin substitution in TB regimens; supports off-label TB use discussion.
- Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384(18):1705-1718. doi:10.1056/NEJMoa2033400 Study 31/A5349 (CDC/ACTG) demonstrating noninferiority of 4-month rifapentine-moxifloxacin regimen for drug-susceptible TB.
- Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599-1608. doi:10.1056/NEJMoa1314210 RIFAQUIN trial testing moxifloxacin-containing shortened TB regimens.
- Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the ATS and IDSA. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST Current ATS/IDSA guideline recommending respiratory fluoroquinolones (including moxifloxacin) for CAP with comorbidities.
- Carr W, Kurbatova E, Starks A, et al. Interim guidance: 4-month rifapentine-moxifloxacin regimen for the treatment of drug-susceptible pulmonary tuberculosis — United States, 2022. MMWR. 2022;71(8):285-289. doi:10.15585/mmwr.mm7108a1 CDC interim guidance for the 4-month TB regimen containing moxifloxacin; basis for off-label TB dosing discussion.
- Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST International guideline recommending moxifloxacin as a core agent for MDR-TB treatment regimens.
- Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61(3):377-392. doi:10.1128/mmbr.61.3.377-392.1997 Foundational review of fluoroquinolone mechanism of action through dual topoisomerase inhibition.
- Stass H, Dalhoff A, Kubitza D, Schuhly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother. 1998;42(8):2060-2065. doi:10.1128/AAC.42.8.2060 Early PK characterization establishing dose-proportional kinetics and half-life parameters.
- Padayatchi N, Naidoo K, Grobler A, Friedland G. A review of moxifloxacin for the treatment of drug-susceptible tuberculosis. J Clin Pharmacol. 2017;57(11):1369-1386. doi:10.1002/jcph.968 Comprehensive review of moxifloxacin PK-PD in TB, including drug interaction with rifamycins reducing moxifloxacin AUC by up to 31%.